Literature DB >> 28007894

The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.

Veronika Reiterer1,2, Cristina Figueras-Puig2, Francois Le Guerroue3, Stefano Confalonieri4,5, Manuela Vecchi6,7, Dasaradha Jalapothu1, Sandip M Kanse1, Raymond J Deshaies6,7, Pier Paolo Di Fiore4,5,8, Christian Behrends9,10, Hesso Farhan11,2,12.   

Abstract

The F-box protein FBXW7 is the substrate-recruiting subunit of an SCF ubiquitin ligase and a major tumor-suppressor protein that is altered in several human malignancies. Loss of function of FBXW7 results in the stabilization of numerous proteins that orchestrate cell proliferation and survival. Little is known about proteins that directly regulate the function of this protein. In the current work, we have mapped the interactome of the enigmatic pseudophosphatase STYX We reasoned that a catalytically inactive phosphatase might have adopted novel mechanisms of action. The STYX interactome contained several F-box proteins, including FBXW7. We show that STYX binds to the F-box domain of FBXW7 and disables its recruitment into the SCF complex. Therefore, STYX acts as a direct inhibitor of FBXW7, affecting the cellular levels of its substrates. Furthermore, we find that levels of STYX and FBXW7 are anti-correlated in breast cancer patients, which affects disease prognosis. We propose the STYX-FBXW7 interaction as a promising drug target for future investigations.
© 2016 The Authors.

Entities:  

Keywords:  Cullin–RING ubiquitin ligase; F‐box protein; breast cancer; mass spectrometry; pseudophosphatase

Mesh:

Substances:

Year:  2016        PMID: 28007894      PMCID: PMC5286380          DOI: 10.15252/embj.201694795

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  45 in total

1.  Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.

Authors:  Masayoshi Yada; Shigetsugu Hatakeyama; Takumi Kamura; Masaaki Nishiyama; Ryosuke Tsunematsu; Hiroyuki Imaki; Noriko Ishida; Fumihiko Okumura; Keiko Nakayama; Keiichi I Nakayama
Journal:  EMBO J       Date:  2004-04-22       Impact factor: 11.598

2.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

Authors:  Ingrid E Wertz; Saritha Kusam; Cynthia Lam; Toru Okamoto; Wendy Sandoval; Daniel J Anderson; Elizabeth Helgason; James A Ernst; Mike Eby; Jinfeng Liu; Lisa D Belmont; Josh S Kaminker; Karen M O'Rourke; Kanan Pujara; Pawan Bir Kohli; Adam R Johnson; Mark L Chiu; Jennie R Lill; Peter K Jackson; Wayne J Fairbrother; Somasekar Seshagiri; Mary J C Ludlam; Kevin G Leong; Erin C Dueber; Heather Maecker; David C S Huang; Vishva M Dixit
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

3.  Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Authors:  Ronan T Swords; Harry P Erba; Daniel J DeAngelo; Dale L Bixby; Jessica K Altman; Michael Maris; Zhaowei Hua; Stephen J Blakemore; Hélène Faessel; Farhad Sedarati; Bruce J Dezube; Francis J Giles; Bruno C Medeiros
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998

4.  Cand1 promotes assembly of new SCF complexes through dynamic exchange of F box proteins.

Authors:  Nathan W Pierce; J Eugene Lee; Xing Liu; Michael J Sweredoski; Robert L J Graham; Elizabeth A Larimore; Michael Rome; Ning Zheng; Bruce E Clurman; Sonja Hess; Shu-ou Shan; Raymond J Deshaies
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

5.  Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.

Authors:  Maryna Gorelik; Stephen Orlicky; Maria A Sartori; Xiaojing Tang; Edyta Marcon; Igor Kurinov; Jack F Greenblatt; Mike Tyers; Jason Moffat; Frank Sicheri; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

6.  Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

Authors:  Chia-Hsin Chan; John Kenneth Morrow; Chien-Feng Li; Yuan Gao; Guoxiang Jin; Asad Moten; Loren J Stagg; John E Ladbury; Zhen Cai; Dazhi Xu; Christopher J Logothetis; Mien-Chie Hung; Shuxing Zhang; Hui-Kuan Lin
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

7.  Spatial control of Cdc42 signalling by a GM130-RasGRF complex regulates polarity and tumorigenesis.

Authors:  Francesco Baschieri; Stefano Confalonieri; Giovanni Bertalot; Pier Paolo Di Fiore; Wolfgang Dietmaier; Marcel Leist; Piero Crespo; Ian G Macara; Hesso Farhan
Journal:  Nat Commun       Date:  2014-09-11       Impact factor: 14.919

8.  Parallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via BACH1 repressor turnover.

Authors:  Meng-Kwang Marcus Tan; Hui-Jun Lim; Eric J Bennett; Yang Shi; J Wade Harper
Journal:  Mol Cell       Date:  2013-09-12       Impact factor: 17.970

9.  Network organization of the human autophagy system.

Authors:  Christian Behrends; Mathew E Sowa; Steven P Gygi; J Wade Harper
Journal:  Nature       Date:  2010-06-20       Impact factor: 49.962

10.  Fbw7 dimerization determines the specificity and robustness of substrate degradation.

Authors:  Markus Welcker; Elizabeth A Larimore; Jherek Swanger; Maria T Bengoechea-Alonso; Jonathan E Grim; Johan Ericsson; Ning Zheng; Bruce E Clurman
Journal:  Genes Dev       Date:  2013-12-01       Impact factor: 11.361

View more
  13 in total

1.  FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation.

Authors:  Yvonne T Kschonsak; Barbara Vodicska; Kai T Richter; Ingrid Hoffmann
Journal:  Cell Death Differ       Date:  2019-07-08       Impact factor: 15.828

2.  The pseudophosphatase STYX targets the F-box of FBXW7 and inhibits SCFFBXW7 function.

Authors:  Veronika Reiterer; Cristina Figueras-Puig; Francois Le Guerroue; Stefano Confalonieri; Manuela Vecchi; Dasaradha Jalapothu; Sandip M Kanse; Raymond J Deshaies; Pier Paolo Di Fiore; Christian Behrends; Hesso Farhan
Journal:  EMBO J       Date:  2016-12-22       Impact factor: 11.598

3.  Evolutionary genomic relationships and coupling in MK-STYX and STYX pseudophosphatases.

Authors:  Yi Qi; Di Kuang; Kylan Kelley; William J Buchser; Shantá D Hinton
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

4.  Composition and Regulation of the Cellular Repertoire of SCF Ubiquitin Ligases.

Authors:  Justin M Reitsma; Xing Liu; Kurt M Reichermeier; Annie Moradian; Michael J Sweredoski; Sonja Hess; Raymond J Deshaies
Journal:  Cell       Date:  2017-11-02       Impact factor: 41.582

Review 5.  Physiological functions of FBW7 in cancer and metabolism.

Authors:  Kouhei Shimizu; Naoe Taira Nihira; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Cell Signal       Date:  2018-02-21       Impact factor: 4.315

6.  MK-STYX Alters the Morphology of Primary Neurons, and Outgrowths in MK-STYX Overexpressing PC-12 Cells Develop a Neuronal Phenotype.

Authors:  Dallas A Banks; Arya Dahal; Alexander G McFarland; Brittany M Flowers; Christina A Stephens; Benjamin Swack; Ayele Gugssa; Winston A Anderson; Shantá D Hinton
Journal:  Front Mol Biosci       Date:  2017-11-16

7.  Identification of crucial genes in abdominal aortic aneurysm by WGCNA.

Authors:  Siliang Chen; Dan Yang; Chuxiang Lei; Yuan Li; Xiaoning Sun; Mengyin Chen; Xiao Wu; Yuehong Zheng
Journal:  PeerJ       Date:  2019-10-08       Impact factor: 2.984

8.  Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.

Authors:  Naphannop Sereesongsaeng; Sara H McDowell; James F Burrows; Christopher J Scott; Roberta E Burden
Journal:  Breast Cancer Res       Date:  2020-12-09       Impact factor: 6.466

Review 9.  The Roles of Pseudophosphatases in Disease.

Authors:  Andrew M Mattei; Jonathan D Smailys; Emma Marie Wilber Hepworth; Shantá D Hinton
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

10.  UBTOR/KIAA1024 regulates neurite outgrowth and neoplasia through mTOR signaling.

Authors:  Hefei Zhang; Quan Zhang; Ge Gao; Xinjian Wang; Tiantian Wang; Zhitao Kong; Guoxiang Wang; Cuizhen Zhang; Yun Wang; Gang Peng
Journal:  PLoS Genet       Date:  2018-08-06       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.